Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: PAXIL CR

Summary for Tradename: PAXIL CR

Suppliers: see list5
patent expirations by year for

Pharmacology for Tradename: PAXIL CR

Clinical Trials for: PAXIL CR

Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male Subjects
Status: Completed Condition: Depressive Disorder; Healthy Volunteer

Pharmacokinetic Evaluation of Brisdelleā„¢ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women
Status: Completed Condition: Postmenopausal Symptoms

Eight-Week Efficacy & Safety Study of Brisdelleā„¢ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause
Status: Completed Condition: Hot Flashes

Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome
Status: Completed Condition: Fibromyalgia Syndrome

Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement
Status: Recruiting Condition: Major Depression

Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)
Status: Terminated Condition: Depressive Disorder

Paxil CR Bioequivalence Study Brazil - Fed Administration
Status: Completed Condition: Depressive Disorder; Healthy Volunteers

PAXIL CR Bioequivalence Study
Status: Completed Condition: Two Single Doses of Controlled Release Paroxetine Given 14 Days Apart; Depressive Disorder; Healthy Volunteer

Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)
Status: Completed Condition: Depressive Disorder; Major Depressive Disorder (MDD)

A Local Register Study For Major Depression Of Paroxetine Controlled Release
Status: Completed Condition: Depressive Disorder, Major; Major Depressive Disorder (MDD)

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Tecnologies
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936Dec 6, 2000RXYes5,872,132*PED<disabled>Y<disabled>
Apotex Tecnologies
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936Dec 6, 2000RXYes5,900,423*PED<disabled>Y<disabled>
Apotex Tecnologies
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936Dec 6, 2000RXYes6,121,291*PED<disabled>Y<disabled>
Apotex Tecnologies
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936Dec 6, 2000RXYes6,133,289*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: PAXIL CR

Drugname Dosage Strength RLD Submissiondate
paroxetine hydrochlorideExtended-release Tablets37.5 mgPaxil CR5/19/2009
paroxetine hydrochlorideExtended-release Tablets25 mgPaxil CR9/9/2005

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology